Bilateral	B:C0238767
sternal	O
infusion	O
of	O
ropivacaine	O
and	O
length	O
of	O
stay	O
in	O
ICU	O
after	O
cardiac	O
surgery	I:C0018821
with	O
increased	O
respiratory	O
risk	O
:	O
A	O
randomised	O
controlled	I:C0206035
trial	I:C0206035

Bilateral	O
sternal	B:C0038293
infusion	O
of	O
ropivacaine	O
and	O
length	O
of	O
stay	O
in	O
ICU	O
after	O
cardiac	O
surgery	I:C0018821
with	O
increased	O
respiratory	O
risk	O
:	O
A	O
randomised	O
controlled	I:C0206035
trial	I:C0206035

Bilateral	O
sternal	O
infusion	B:C0574032
of	O
ropivacaine	O
and	O
length	O
of	O
stay	O
in	O
ICU	O
after	O
cardiac	O
surgery	I:C0018821
with	O
increased	O
respiratory	O
risk	O
:	O
A	O
randomised	O
controlled	I:C0206035
trial	I:C0206035

Bilateral	O
sternal	O
infusion	O
of	O
ropivacaine	B:C0073571
and	O
length	O
of	O
stay	O
in	O
ICU	O
after	O
cardiac	O
surgery	I:C0018821
with	O
increased	O
respiratory	O
risk	O
:	O
A	O
randomised	O
controlled	I:C0206035
trial	I:C0206035

Bilateral	O
sternal	O
infusion	O
of	O
ropivacaine	O
and	O
length	O
of	O
stay	O
in	O
ICU	B:C0021708
after	O
cardiac	O
surgery	I:C0018821
with	O
increased	O
respiratory	O
risk	O
:	O
A	O
randomised	O
controlled	I:C0206035
trial	I:C0206035

Bilateral	O
sternal	O
infusion	O
of	O
ropivacaine	O
and	O
length	O
of	O
stay	O
in	O
ICU	O
after	O
cardiac	B:C0018821
surgery	I:C0018821
with	O
increased	O
respiratory	O
risk	O
:	O
A	O
randomised	O
controlled	I:C0206035
trial	I:C0206035

Bilateral	O
sternal	O
infusion	O
of	O
ropivacaine	O
and	O
length	O
of	O
stay	O
in	O
ICU	O
after	O
cardiac	O
surgery	I:C0018821
with	O
increased	O
respiratory	O
risk	O
:	O
A	O
randomised	B:C0206035
controlled	I:C0206035
trial	I:C0206035

The	O
continuous	O
bilateral	B:C0238767
infusion	O
of	O
a	O
local	O
anaesthetic	I:C0002934
solution	O
around	O
the	O
sternotomy	O
wound	O
(	O
bilateral	O
sternal	O
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	O
after	O
sternotomy	O
.	O

The	O
continuous	O
bilateral	O
infusion	B:C0574032
of	O
a	O
local	O
anaesthetic	I:C0002934
solution	O
around	O
the	O
sternotomy	O
wound	O
(	O
bilateral	O
sternal	O
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	O
after	O
sternotomy	O
.	O

The	O
continuous	O
bilateral	O
infusion	O
of	O
a	O
local	B:C0002934
anaesthetic	I:C0002934
solution	O
around	O
the	O
sternotomy	O
wound	O
(	O
bilateral	O
sternal	O
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	O
after	O
sternotomy	O
.	O

The	O
continuous	O
bilateral	O
infusion	O
of	O
a	O
local	O
anaesthetic	I:C0002934
solution	B:C0525069
around	O
the	O
sternotomy	O
wound	O
(	O
bilateral	O
sternal	O
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	O
after	O
sternotomy	O
.	O

The	O
continuous	O
bilateral	O
infusion	O
of	O
a	O
local	O
anaesthetic	I:C0002934
solution	O
around	O
the	O
sternotomy	B:C0185792
wound	O
(	O
bilateral	O
sternal	O
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	O
after	O
sternotomy	O
.	O

The	O
continuous	O
bilateral	O
infusion	O
of	O
a	O
local	O
anaesthetic	I:C0002934
solution	O
around	O
the	O
sternotomy	O
wound	B:C0043250
(	O
bilateral	O
sternal	O
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	O
after	O
sternotomy	O
.	O

The	O
continuous	O
bilateral	O
infusion	O
of	O
a	O
local	O
anaesthetic	I:C0002934
solution	O
around	O
the	O
sternotomy	O
wound	O
(	O
bilateral	B:C0238767
sternal	O
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	O
after	O
sternotomy	O
.	O

The	O
continuous	O
bilateral	O
infusion	O
of	O
a	O
local	O
anaesthetic	I:C0002934
solution	O
around	O
the	O
sternotomy	O
wound	O
(	O
bilateral	O
sternal	B:C0038293
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	O
after	O
sternotomy	O
.	O

The	O
continuous	O
bilateral	O
infusion	O
of	O
a	O
local	O
anaesthetic	I:C0002934
solution	O
around	O
the	O
sternotomy	O
wound	O
(	O
bilateral	O
sternal	O
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	B:C0030193
after	O
sternotomy	O
.	O

The	O
continuous	O
bilateral	O
infusion	O
of	O
a	O
local	O
anaesthetic	I:C0002934
solution	O
around	O
the	O
sternotomy	O
wound	O
(	O
bilateral	O
sternal	O
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	O
after	O
sternotomy	B:C0185792
.	O

To	O
assess	O
the	O
effects	O
of	O
the	O
technique	O
on	O
the	O
need	O
for	O
intensive	B:C0085559
care	I:C0085559
in	O
cardiac	O
patients	O
at	O
increased	O
risk	O
of	O
respiratory	O
complications	I:C0161818
.	O

To	O
assess	O
the	O
effects	O
of	O
the	O
technique	O
on	O
the	O
need	O
for	O
intensive	O
care	I:C0085559
in	O
cardiac	O
patients	O
at	O
increased	O
risk	O
of	O
respiratory	B:C0161818
complications	I:C0161818
.	O

Randomised	B:C0206035
,	I:C0206035
observer	I:C0206035
-	I:C0206035
blind	I:C0206035
controlled	I:C0206035
trial	I:C0206035
.	O

Single	O
centre	O
,	O
French	B:C0020028
University	I:C0020028
Hospital	I:C0020028
.	O

In	O
total	O
,	O
120	O
adults	O
scheduled	O
for	O
open	B:C0189745
-	I:C0189745
heart	I:C0189745
surgery	I:C0189745
,	O
with	O
one	O
of	O
the	O
following	O
conditions	O
:	O
age	O
more	O
than	O
75	O
years	O
,	O
BMI	O
>30	O
kg	O
m	O
,	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
,	O
active	O
smoking	O
habit	O
.	O

In	O
total	O
,	O
120	O
adults	O
scheduled	O
for	O
open	O
-	I:C0189745
heart	I:C0189745
surgery	I:C0189745
,	O
with	O
one	O
of	O
the	O
following	O
conditions	O
:	O
age	O
more	O
than	O
75	O
years	O
,	O
BMI	B:C1305855
>30	O
kg	O
m	O
,	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
,	O
active	O
smoking	O
habit	O
.	O

In	O
total	O
,	O
120	O
adults	O
scheduled	O
for	O
open	O
-	I:C0189745
heart	I:C0189745
surgery	I:C0189745
,	O
with	O
one	O
of	O
the	O
following	O
conditions	O
:	O
age	O
more	O
than	O
75	O
years	O
,	O
BMI	O
>30	O
kg	O
m	O
,	O
chronic	B:C0024117
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
,	O
active	O
smoking	O
habit	O
.	O

Either	O
a	O
bilateral	B:C0238767
sternal	O
infusion	O
of	O
0.2	O
%	O
ropivacaine	O
(	O
3	O
ml	O
h	O
through	O
each	O
catheter	O
;	O
'	O
intervention	I:C2986530
'	I:C2986530
group	I:C2986530
)	O
,	O
or	O
standardised	O
care	O
only	O
(	O
'	O
control	O
'	O
group	O
)	O
.	O

Either	O
a	O
bilateral	O
sternal	B:C0038293
infusion	O
of	O
0.2	O
%	O
ropivacaine	O
(	O
3	O
ml	O
h	O
through	O
each	O
catheter	O
;	O
'	O
intervention	I:C2986530
'	I:C2986530
group	I:C2986530
)	O
,	O
or	O
standardised	O
care	O
only	O
(	O
'	O
control	O
'	O
group	O
)	O
.	O

Either	O
a	O
bilateral	O
sternal	O
infusion	B:C0574032
of	O
0.2	O
%	O
ropivacaine	O
(	O
3	O
ml	O
h	O
through	O
each	O
catheter	O
;	O
'	O
intervention	I:C2986530
'	I:C2986530
group	I:C2986530
)	O
,	O
or	O
standardised	O
care	O
only	O
(	O
'	O
control	O
'	O
group	O
)	O
.	O

Either	O
a	O
bilateral	O
sternal	O
infusion	O
of	O
0.2	O
%	O
ropivacaine	B:C0073571
(	O
3	O
ml	O
h	O
through	O
each	O
catheter	O
;	O
'	O
intervention	I:C2986530
'	I:C2986530
group	I:C2986530
)	O
,	O
or	O
standardised	O
care	O
only	O
(	O
'	O
control	O
'	O
group	O
)	O
.	O

Either	O
a	O
bilateral	O
sternal	O
infusion	O
of	O
0.2	O
%	O
ropivacaine	O
(	O
3	O
ml	O
h	O
through	O
each	O
catheter	B:C0085590
;	O
'	O
intervention	I:C2986530
'	I:C2986530
group	I:C2986530
)	O
,	O
or	O
standardised	O
care	O
only	O
(	O
'	O
control	O
'	O
group	O
)	O
.	O

Either	O
a	O
bilateral	O
sternal	O
infusion	O
of	O
0.2	O
%	O
ropivacaine	O
(	O
3	O
ml	O
h	O
through	O
each	O
catheter	O
;	O
'	B:C2986530
intervention	I:C2986530
'	I:C2986530
group	I:C2986530
)	O
,	O
or	O
standardised	O
care	O
only	O
(	O
'	O
control	O
'	O
group	O
)	O
.	O

Analgesia	B:C3202977
was	O
provided	O
with	O
paracetamol	O
and	O
self	O
-	O
administered	O
intravenous	O
morphine	O
.	O

Analgesia	O
was	O
provided	O
with	O
paracetamol	B:C0000970
and	O
self	O
-	O
administered	O
intravenous	O
morphine	O
.	O

Analgesia	O
was	O
provided	O
with	O
paracetamol	O
and	O
self	O
-	O
administered	O
intravenous	O
morphine	B:C0026549
.	O

The	O
length	O
of	O
time	O
to	O
readiness	B:C1318963
for	O
discharge	O
from	O
ICU	O
,	O
blindly	O
assessed	O
by	O
a	O
committee	O
of	O
experts	O
.	O

The	O
length	O
of	O
time	O
to	O
readiness	O
for	O
discharge	B:C0030685
from	O
ICU	O
,	O
blindly	O
assessed	O
by	O
a	O
committee	O
of	O
experts	O
.	O

The	O
length	O
of	O
time	O
to	O
readiness	O
for	O
discharge	O
from	O
ICU	B:C0021708
,	O
blindly	O
assessed	O
by	O
a	O
committee	O
of	O
experts	O
.	O

The	O
length	O
of	O
time	O
to	O
readiness	O
for	O
discharge	O
from	O
ICU	O
,	O
blindly	O
assessed	O
by	O
a	O
committee	O
of	O
experts	B:C0009817
.	O

No	O
effect	O
was	O
found	O
between	O
groups	O
for	O
the	O
primary	O
outcome	O
(	O
P	O
=	O
0.680	O
,	O
intention	B:C2718028
to	I:C2718028
treat	I:C2718028
)	O
;	O
the	O
median	O
values	O
were	O
42.4	O
and	O
37.7	O
h	O
,	O
respectively	O
for	O
the	O
control	O
and	O
intervention	O
groups	I:C2986530
(	O
P	O
=	O
0.873	O
)	O
.	O

No	O
effect	O
was	O
found	O
between	O
groups	O
for	O
the	O
primary	O
outcome	O
(	O
P	O
=	O
0.680	O
,	O
intention	O
to	I:C2718028
treat	I:C2718028
)	O
;	O
the	O
median	O
values	O
were	O
42.4	O
and	O
37.7	O
h	O
,	O
respectively	O
for	O
the	O
control	O
and	O
intervention	B:C2986530
groups	I:C2986530
(	O
P	O
=	O
0.873	O
)	O
.	O

Similar	O
nonsignificant	O
trends	O
were	O
noted	O
for	O
other	O
postoperative	B:C0241311
delays	O
.	O

Significant	O
effects	O
favouring	O
the	O
intervention	B:C0184661
were	O
noted	O
for	O
dynamic	O
pain	I:C0030193
,	O
patient	O
satisfaction	O
,	O
occurrence	O
of	O
nausea	O
and	O
vomiting	O
,	O
occurrence	O
of	O
delirium	O
or	O
mental	O
confusion	I:C0009676
and	O
occurrence	O
of	O
pulmonary	O
complications	I:C0281169
.	O

Significant	O
effects	O
favouring	O
the	O
intervention	O
were	O
noted	O
for	O
dynamic	B:C0030193
pain	I:C0030193
,	O
patient	O
satisfaction	O
,	O
occurrence	O
of	O
nausea	O
and	O
vomiting	O
,	O
occurrence	O
of	O
delirium	O
or	O
mental	O
confusion	I:C0009676
and	O
occurrence	O
of	O
pulmonary	O
complications	I:C0281169
.	O

Significant	O
effects	O
favouring	O
the	O
intervention	O
were	O
noted	O
for	O
dynamic	O
pain	I:C0030193
,	O
patient	O
satisfaction	O
,	O
occurrence	O
of	O
nausea	O
and	O
vomiting	B:C0042963
,	O
occurrence	O
of	O
delirium	O
or	O
mental	O
confusion	I:C0009676
and	O
occurrence	O
of	O
pulmonary	O
complications	I:C0281169
.	O

Significant	O
effects	O
favouring	O
the	O
intervention	O
were	O
noted	O
for	O
dynamic	O
pain	I:C0030193
,	O
patient	O
satisfaction	O
,	O
occurrence	O
of	O
nausea	O
and	O
vomiting	O
,	O
occurrence	O
of	O
delirium	B:C0011206
or	O
mental	O
confusion	I:C0009676
and	O
occurrence	O
of	O
pulmonary	O
complications	I:C0281169
.	O

Significant	O
effects	O
favouring	O
the	O
intervention	O
were	O
noted	O
for	O
dynamic	O
pain	I:C0030193
,	O
patient	O
satisfaction	O
,	O
occurrence	O
of	O
nausea	O
and	O
vomiting	O
,	O
occurrence	O
of	O
delirium	O
or	O
mental	B:C0009676
confusion	I:C0009676
and	O
occurrence	O
of	O
pulmonary	O
complications	I:C0281169
.	O

Significant	O
effects	O
favouring	O
the	O
intervention	O
were	O
noted	O
for	O
dynamic	O
pain	I:C0030193
,	O
patient	O
satisfaction	O
,	O
occurrence	O
of	O
nausea	O
and	O
vomiting	O
,	O
occurrence	O
of	O
delirium	O
or	O
mental	O
confusion	I:C0009676
and	O
occurrence	O
of	O
pulmonary	B:C0281169
complications	I:C0281169
.	O

In	O
12	O
patients	O
,	O
although	O
no	O
symptoms	B:C1457887
actually	O
occurred	O
,	O
the	O
total	O
ropivacaine	O
plasma	O
level	O
exceeded	O
the	O
lowest	O
value	O
for	O
which	O
neurological	O
symptoms	I:C0235031
have	O
been	O
observed	O
in	O
healthy	O
volunteers	I:C1708335
.	O

In	O
12	O
patients	O
,	O
although	O
no	O
symptoms	O
actually	O
occurred	O
,	O
the	O
total	O
ropivacaine	O
plasma	O
level	O
exceeded	O
the	O
lowest	O
value	O
for	O
which	O
neurological	B:C0235031
symptoms	I:C0235031
have	O
been	O
observed	O
in	O
healthy	O
volunteers	I:C1708335
.	O

In	O
12	O
patients	O
,	O
although	O
no	O
symptoms	O
actually	O
occurred	O
,	O
the	O
total	O
ropivacaine	O
plasma	O
level	O
exceeded	O
the	O
lowest	O
value	O
for	O
which	O
neurological	O
symptoms	I:C0235031
have	O
been	O
observed	O
in	O
healthy	B:C1708335
volunteers	I:C1708335
.	O

Because	O
of	O
a	O
small	O
size	O
effect	O
,	O
and	O
despite	O
significant	O
analgesic	B:C0948482
effects	I:C0948482
,	O
this	O
strategy	O
failed	O
to	O
reduce	O
the	O
time	O
spent	O
in	O
ICU	O
.	O

Because	O
of	O
a	O
small	O
size	O
effect	O
,	O
and	O
despite	O
significant	O
analgesic	O
effects	I:C0948482
,	O
this	O
strategy	O
failed	O
to	O
reduce	O
the	O
time	O
spent	O
in	O
ICU	B:C0021708
.	O

EudraCT	O
(	O
NÂ°	O
:	O
2012-005225-69	O
)	O
;	O
ClinicalTrials.gov	B:C4086204
(	O
NCT01828788	O
)	O
.	O

